PIK3CA and breast cancer: Finally, treatment pressure can also lead to the acquisition of PTEN loss, as observed in PIK3CA mutant metastatic breast cancer patients that developed resistance to the p110α-specific PI3K inhibitor apelisib (BYL719) [85].